Monopar Therapeutics (MNPR) Operating cash flow 2016–2025
Monopar Therapeutics (MNPR) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$12.2MFY2025 · since FY2016: -$1.2M → -$12.2M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$12.2M | -90.5% |
| FY2024 | -$6.4M | +18.5% |
| FY2023 | -$7.9M | -8.7% |
| FY2022 | -$7.2M | +1.2% |
| FY2021 | -$7.3M | -56.9% |
| FY2020 | -$4.7M | -54.5% |
| FY2019 | -$3.0M | -12.6% |
| FY2018 | -$2.7M | -2.0% |
| FY2017 | -$2.6M | -119.9% |
| FY2016 | -$1.2M | — |
Source: SEC XBRL filings · For reference only · Not investment advice